Research and Development

Schering-Plough Research Institute (SPRI) is the human pharmaceutical research unit of Schering-Plough Corporation, a global science-based healthcare company with prescription, consumer and animal health products.  We have a strong R&D engine, with laboratories around the world, including our UK R&D facility in Newhouse, Scotland, specialising in central nervous system (psychiatry and analgesia) and cardiovascular/metabolic disease research.

Other R&D laboratories worldwide include:

  • Cambridge, Massachusetts - biologics in oncology, small molecules in oncology, inflammation/autoimmunity and screening technologies

  • Mexico City, Mexico – pharmaceutical development

  • New Jersey – several laboratory sites in New Jersey together encompass all areas of R&D. The largest New Jersey laboratory facility is on the Kenilworth campus, the site of the company’s global headquarters

  • Newhouse, Scotland –  specialising in central nervous system (psychiatry and analgesia) and cardiovascular/metabolic disease research

  • Oss, the Netherlands – research, specializing in women’s health (contraception, fertility, osteoporosis and endometriosis), oncology research related to endocrinology and immunology (inflammation for rheumatoid arthritis)

  • Palo Alto, California (Schering-Plough Biopharma) – biotech research, specializing in oncology and inflammation

  • Riom, France – preclinical development

  • Schachen (canton of Lucerne), Switzerland – our Werthenstein Chemie AG focuses on chemistry, biotechnology and clinical packaging, which also comprises the area of analysis and research

  • Tokyo and Osaka, Japan – focusing on pre-clinical and clinical development for products for Japan

  • Waltrop, Germany – preclinical development  

SPRI has one of the richest and most diverse late-stage pipelines in the industry today, with a strategic balance of biotech, including vaccines and small molecules. Additionally, we believe it is important to focus on basic research to feed the early-stage pipeline with drug candidates. In this way, SPRI is able to maintain a continual flow of innovative therapies to meet patient needs.


Our R&D programme includes both primary and specialty care projects in the therapeutic areas of cardiovascular, central nervous system, immunology and infectious diseases, oncology, respiratory and women’s health.
Click here to be re-directed to our global website to see more information on our pipeline.

Link to http://www.schering-plough.com/binaries/Products-in-Development.pdf